Bullish
$MYOV 's Relugolix very very bad for $EPIX. Relugolix Phase 3 data met primary endpoints for prostate cancer "data is as good as it gets". NDA will surely be fasr tracked. Sorry EPIX, serious competition in the cancer business. Hard to compete in this arena with rent by the hour office space and part time ceos
  • 2
  • 29